Goldman Sachs initiated coverage on Design Therapeutics with a new price target

1/19/22 5:39:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Goldman Sachs initiated coverage of Design Therapeutics with a rating of Sell and set a new price target of $10.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DSGN

Date	Price Target	Rating	Analyst
5/7/2024	$6.00 → $12.00	Neutral → Overweight	Piper Sandler
11/14/2023	$42.00 → $6.00	Overweight → Neutral	Piper Sandler
8/15/2023	$19.00 → $6.00	Outperform → Neutral	Wedbush
8/15/2023	$23.00 → $7.00	Outperform → Sector Perform	RBC Capital Mkts
8/15/2023	$6.00	Outperform → Market Perform	SVB Securities
5/4/2023	$6.00	Sell → Neutral	Goldman
6/10/2022	$21.00	Outperform	Wedbush
5/2/2022	$30.00	Outperform	RBC Capital Mkts